Rolapitant Submitted for Approval for Prevention of Chemo-Induced Nausea and Vomiting
the Cancer Therapy Advisor take:
Tesaro, Inc. has announced that it has submitted a new drug application for its drug, rolapitant, to the U.S. Food and Drug Administration for the prevention of chemotherapy-induced nausea and vomiting (CINV). Rolapitant is a neurokinin-1 (NK-1) receptor antagonist that is being developed as both oral and intravenous formulations. Rolapitant has been studied in about 1,400 patients receiving chemotherapy, a treatment which commonly causes nausea and vomiting.
Rolapitant was studied in combination with granisetron, a 5-HT3 receptor antagonist, and dexamethasone in patients treated with carboplatin, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, epirubicin, or irinotecan. Researchers found that those treated with the rolapitant, granisetron, and dexamethasone had a significantly higher complete response rate compared with those that received only granisetron and dexamethasone for delayed phase CINV (P<0.001).
Researchers estimate that over 70% of patients with cancer undergoing chemotherapy experience CINV. If not prevented, CINV may decrease quality of life during cancer treatment, as well as delay or force the discontinuation of treatment with chemotherapy. Untreated nausea and vomiting can result in dehydration and malnutrition, thereby resulting in hospitalization.
Reduced Mortality Linked to Use of Statins in Patients With Colorectal Cancer
OPKO Health, Inc. OPK, reported that its licensee, TESARO, Inc. TSRO, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
This NDA is supported by data from four controlled studies covering a spectrum of patients receiving chemotherapy that commonly causes nausea and vomiting. The top-line results of three of the Phase 3 studies were previously announced by TESARO and were presented in detail at the American Society for Clinical Oncology (ASCO) annual meeting in June 2014.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin on Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer